These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 20507799)

  • 41. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
    Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
    Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis.
    Pitt M; Crathorne L; Moxham T; Bond M; Hyde C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):41-6. PubMed ID: 21047490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Ho JC; Hsieh ML; Chuang PH; Hsieh VC
    Value Health Reg Issues; 2018 May; 15():120-126. PubMed ID: 29704658
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
    Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
    Thein HH; Qiao Y; Zaheen A; Jembere N; Sapisochin G; Chan KKW; Yoshida EM; Earle CC
    PLoS One; 2017; 12(10):e0185198. PubMed ID: 29016627
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma.
    Liao W; Huang J; Hutton D; Zhu G; Wu Q; Wen F; Bai L; Li Q
    Liver Int; 2019 Dec; 39(12):2408-2416. PubMed ID: 31544330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rimonabant for the treatment of overweight and obese people.
    Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
    Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health-related quality of life and sorafenib.
    Spinzi G; Terreni N
    Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
    [No Abstract]   [Full Text] [Related]  

  • 50. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Hamilton J; Stevens J; Rowntree C; Martyn-St James M; Rawdin A; Wong R
    Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
    Iavarone M; Cabibbo G; Piscaglia F; Zavaglia C; Grieco A; Villa E; Cammà C; Colombo M;
    Hepatology; 2011 Dec; 54(6):2055-63. PubMed ID: 21898496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
    Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cetuximab for the first-line treatment of metastatic colorectal cancer.
    Meads C; Round J; Tubeuf S; Moore D; Pennant M; Bayliss S
    Health Technol Assess; 2010 May; 14 Suppl 1():1-8. PubMed ID: 20507797
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Leung HW; Liu CF; Chan AL
    Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
    Green C; Dinnes J; Takeda A; Shepherd J; Hartwell D; Cave C; Payne E; Cuthbertson BH
    Health Technol Assess; 2005 Mar; 9(11):1-126, iii-iv. PubMed ID: 15774234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
    Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
    Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Rimassa L; Santoro A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
    Wörns MA; Schuchmann M; Düber C; Otto G; Galle PR; Weinmann A
    Oncology; 2010; 79(1-2):85-92. PubMed ID: 21071995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.